Study with Diamyd Medical’s diabetes vaccine awarded EU-funding

        Print
| Source: Diamyd Medical AB (publ)
Diamyd Medical (NASDAQ OMX First North, Ticker: DMYD B) informs that the ongoing
combination study DIABGAD has been awarded EUR 120 000, corresponding to about
SEK 1.1 million, in EU-funding. The grant comes from an FP7 project where
Linköping University and Diamyd Medical are included. The DIABGAD study aims to
evaluate whether vitamin D and ibuprofen act synergistically with the diabetes
vaccine Diamyd® in order to preserve the insulin producing capacity in children
newly diagnosed with type 1 diabetes. The first results from the study are
expected to be presented in the beginning of 2015.
“It is truly encouraging that the EU chooses to support DIABGAD,” says Professor
Johnny Ludvigsson at Linköping University, who is the lead investigator and
sponsor of the study. “This funding helps and strengthens us in our efforts to
reach a new combination therapy for type 1 diabetes.”

“The combination program for the diabetes vaccine Diamyd® is of interest to both
researchers and industry,” says Anders Essen-Möller, Chairman of Diamyd Medical.
“The funding from the EU reflects this and the concept will be discussed further
with Diamyd Medical's Scientific Advisory Board on September 16 in conjunction
with a European diabetes conference in Vienna.”

Type 1 diabetes is an autoimmune disease where the immune system attacks the
patients’ own insulin producing beta cells. For these patients, daily treatment
with insulin is mandatory to sustain life. The importance of finding a cure is
high for the world’s health care systems and the wellbeing of patients. The
annual market for an easy to use, successful therapeutic is estimated to several
billion dollars.

About Diamyd®
Diamyd® is a therapeutic under development for the treatment and prevention of
autoimmune diabetes. Diamyd® has been used in trials totaling more than one
thousand patients with an excellent safety profile. Diamyd has shown an overall
16% efficacy (p=0.1) versus placebo regarding preservation of the patients’
endogenous insulin secretion in a European Phase III trial and is currently
being further developed in combination regimens with other therapeutic
compounds. Diamyd® is easy to administer in any clinical setting.
For further information, please contact:
Anders Essen-Möller, Chairman Diamyd Medical AB
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
About Diamyd Medical
Diamyd Medical is dedicated to fight type 1 diabetes and to work towards a cure
for the disease. Diamyd Medical’s current projects include development of
combination regimens for arresting the successive destruction of insulin
producing beta cells using the Company’s GAD65-based diabetes vaccine, such as
for example Diamyd®+ Vitamin D with or without an anti-inflammatory compound;
and Diamyd®+ GABA, for which Diamyd Medical licenses exclusive intellectual
rights from the University of California in Los Angeles (UCLA). Diamyd Medical
has further acquired 46% of the stem cell company Cellaviva AB that is
establishing a Swedish commercial bank for private family saving of umbilical
cord blood and other sources of stem cells. Stem cells are required for
Personalized Regenerative Medicine (PRM), for example to restore beta cell mass
in diabetes patients where autoimmunity has been arrested.

Remium Nordic AB is the Company’s Certified Adviser.

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.